Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adagrasib: First Approval.

Drugs - 1 Feb 2023

Dhillon Sohita

Abstract excerpt

Adagrasib (KRAZATI™) is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 36763320
DOI: 10.1007/s40265-023-01839-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adagrasib: First Approval.PMID 36763320Read ↗

First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Fulzerasib: First Approval.Semantic proximity Read ↗

Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy.Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.